The standard chemotherapeutic options for osteosarcoma are cisplatin, methotrexate, and doxorubicin which have been used for more than 40 years in clinics.[2] Osteosarcoma patients are usually associated with symptoms of bone loss and pathological fracture, which are closely related to disrupted bone homeostasis in the tumor environment.[3] Osteosarcoma cells overexpress the receptor activator of nuclear factor‐κB ligand (RANKL). This evidence concerns the gene TNFSF11 and neoplasm.